Cybin Inc. announced additional strategic partnership agreements (SPAs), bringing the total to 18 clinical sites engaged to advance its multinational Phase 3 program evaluating CYB003. This program is for the adjunctive treatment of Major Depressive Disorder (MDD).
The APPROACH study, part of the PARADIGM program, is expected to include approximately 45 clinical sites. The expanded network includes experienced neuropsychiatric drug trial partners, such as Kimball A. Johnson, M.D., and Paul Thielking.
This SPA model is designed to promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving patient recruitment. The goal is to streamline trial operations and potentially reduce the time to completion for the pivotal Phase 3 program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.